Study Results: 78.3% of Cats Recovered with Dual Antiviral Feline Infectious Peritonitis (FIP) Treatment, Including Previously Relapsed Cases
- BasmiFIP Philippines
- 5 days ago
- 5 min read
The BasmiFIP field evaluation of 46 cats demonstrates that combined GS-441524 and EIDD-1931 oral therapy is effective, safe, and works even when single-drug treatment has failed.
Evidence from Real Cats, Real Owners
Published clinical trials from university laboratories are important. But cat owners want to know something more specific: does this treatment actually work for cats like mine, treated at home, in real-world conditions?
The 2024 field evaluation conducted by Li and Cheah under the BasmiFIP initiative answers that question with data from 46 real cats, treated by their owners, tracked daily, and followed for six months. These were not carefully selected laboratory subjects. They were household cats with Feline Infectious Peritonitis (FIP), many of whom had already been through treatment before and relapsed.
What the Study Did
Between June and September 2024, 46 domestic cats diagnosed with Feline Infectious Peritonitis (FIP) were enrolled. The cohort included all Feline Infectious Peritonitis (FIP) types: wet (effusive), dry (non-effusive), neurological, and ocular presentations. Various breeds and ages were represented. About 90% were indoor-only cats.
Each cat received a standardized oral capsule containing both GS-441524 (10-15 mg/kg once daily) and EIDD-1931 (5 mg for cats under 4.5 kg, or 10 mg/kg for cats 4.5 kg and above). Treatment lasted 60 days, with one capsule per 2.5 kg of body weight every 24 hours.
What makes this study particularly valuable is the patient population. A significant number of enrolled cats had previously relapsed after completing a full course of GS-441524 monotherapy. These are not easy cases. When a cat relapses after completing 84 days of GS-441524, it typically means the virus has developed some degree of resistance to the drug. Treating these cases is inherently more difficult than treating first-time patients.
Owners tracked daily weight, appetite, clinical signs, and any side effects through an online form. Veterinary validation was obtained where possible. All cats were followed for 180 days after treatment ended.
The Results
78.3% achieved clinical remission. 36 of the 46 cats reached full clinical remission following the 60-day dual antiviral protocol. No remaining Feline Infectious Peritonitis (FIP) symptoms after treatment.
Only 6.5% relapsed. During the 180-day follow-up, just 3 cats experienced a return of symptoms. This is remarkably low, especially considering that many of these cats had already relapsed once before on single-drug therapy. For context, published GS-441524 monotherapy studies report relapse rates of approximately 10-11% in populations that have never been treated before.
10.9% mortality. 5 cats did not survive. The authors noted these were generally cats with the most advanced disease at enrollment, reinforcing the importance of starting treatment early before organ damage becomes irreversible.
91% showed weight gain and improved appetite. By mid-treatment, 42 of the 46 cats had documented weight gain and appetite improvement through daily owner logs. Consistent weight recovery is one of the clearest real-world signals that antiviral treatment is successfully suppressing the virus.
A:G ratio improved from 0.35 to 0.62. The albumin-to-globulin ratio, a key blood marker for Feline Infectious Peritonitis (FIP) disease activity, improved steadily throughout treatment. By Day 30, it had already risen to approximately 0.45, and by Day 60, it reached 0.62. This progressive improvement demonstrates that the inflammatory response was actively resolving.
Minimal side effects. Only 2 cats experienced adverse events: minor gastrointestinal issues and brief lethargy during early dosing. Both resolved without intervention. No severe toxicity. No treatment discontinuations.
Why 78.3% Remission in This Population Is a Strong Result
The approximately 92% remission rate commonly cited for GS-441524 treatment comes from studies of cats being treated for the first time. The BasmiFIP study included a significant proportion of cats that had already relapsed after a full course of GS-441524. Treating drug-resistant Feline Infectious Peritonitis (FIP) is fundamentally harder.
In this context, achieving 78.3% remission is clinically significant. And the 6.5% relapse rate is actually lower than what first-time monotherapy studies typically report (10-11%). This suggests the dual mechanism of GS-441524 (chain termination) plus EIDD-1931 (lethal mutagenesis) provides more durable viral suppression, even when the virus has already demonstrated resistance to single-drug therapy.
How the Two Antivirals Work Together
The strength of this protocol lies in its dual-mechanism approach. GS-441524 and EIDD-1931 attack the Feline Infectious Peritonitis (FIP) virus through completely different pathways.
GS-441524 blocks viral replication directly by terminating the RNA chain. The virus cannot make new copies of itself.
EIDD-1931 corrupts whatever copies still manage to form by introducing errors into the viral genetic code. With each replication attempt, these errors accumulate until the genome becomes nonfunctional. The virus destroys itself through its own defective copies.
Together, they create a dual barrier that the virus must overcome simultaneously to survive. Developing resistance to both mechanisms at the same time is statistically far less probable than developing resistance to either one alone.
What This Means for Cat Owners in the Philippines
If your cat has Feline Infectious Peritonitis (FIP), whether it is a first diagnosis or a relapse, this study provides practical evidence that dual antiviral therapy works in real-world conditions.
It works for the hardest cases. Many cats in this study had already failed GS-441524 monotherapy and still achieved remission with the dual protocol.
Relapse is rare. Only 6.5% relapsed over 180 days. The dual mechanism appears to provide stronger long-term viral suppression.
It is safe. Only 2 minor side effects across 46 cats. No severe reactions. No cats needed to stop treatment.
It is practical. One oral capsule per day. No injections. No complex multi-drug schedules. Manageable for home treatment.
Early treatment matters. The cats that did not survive had the most advanced disease. Starting treatment promptly is still the most important factor.
Study Limitations
This was an observational field study without a randomized control group. Some data was owner-reported. Pharmacokinetic studies and randomized trials are needed to further validate the results. But the real-world conditions, diverse patient population, and inclusion of previously relapsed cats make this study a meaningful contribution to the Feline Infectious Peritonitis (FIP) treatment evidence base.
Read the Full Study
Want to dive deeper into the methodology, data, and clinical analysis? Download or read the complete research paper.
"Enhancing FIP Therapeutic Outcomes: A Field-Based Evaluation of Combined Oral GS-441524 and EIDD-1931 Protocols" by Li, Y. & Cheah, B. (2024). BasmiFIP Initiative.
To learn more or consult about your cat's treatment, visit basmifipphilippines.com or reach the BasmiFIP Philippines team on WhatsApp.
Free consultations available. Every day matters, and the right support makes all the difference.
Reference: Li, Y. & Cheah, B. (2024). Enhancing FIP Therapeutic Outcomes: A Field-Based Evaluation of Combined Oral GS-441524 and EIDD-1931 Protocols. BasmiFIP Initiative.
Comments